Baker v. Wright Medical Technology, Inc.

CourtDistrict Court, E.D. California
DecidedAugust 19, 2020
Docket2:20-cv-00823
StatusUnknown

This text of Baker v. Wright Medical Technology, Inc. (Baker v. Wright Medical Technology, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Baker v. Wright Medical Technology, Inc., (E.D. Cal. 2020).

Opinion

WwAOwe 2.4 UV VVUL □□ INVIVIT INGEN PYVLULITIOCTIt 2 PHM Vora payt +tviv FILED. EASTERN DISTRICT ARKANS UNITED STATES JUDICIAL PANEL AUG 1 4 2020 on MULTIDISTRICT LITIGATION JAMES WeACCORMACK, CL FILED IN RE: PROFEMUR HIP IMPLANT Aug 19. 2020 PRODUCTS LIABILITY LITIGATION CLERK, rsyaier court MDL No. 2949

TRANSFER ORDER

Before the Panel: Plaintiffs in the Eastern District of Arkansas Simpson action and the Western District of Wisconsin Chadderdon action move under 28 U.S.C. § 1407 to centralize pretrial proceedings in the Eastern District of Arkansas. These cases concern alleged defects in the Wright Medical and Microport Profemur line of modular hip implants, which were offered in titanium and cobalt chromium alloys. Plaintiffs’ motion includes the 41 actions listed on Schedule A,' which are pending in 25 districts. Since plaintiffs filed this motion, the parties have notified the Panel of 21 additional potentially related actions.? Wright Medical defendants’ and MicroPort Orthopedics Inc. oppose centralization. Ifan MDL | is created, they suggest centralization in the Eastern District of Arkansas. Plaintiffs in seventeen actions support centralization. They disagree as to selection of transferee district, but suggest the following: the Eastern District of Arkansas (primary choice of plaintiffs in fifteen cases, alternative choice of plaintiffs in two cases), the District of Minnesota (primary choice of plaintiffs in two cases, alternative choice of plaintiffs in five cases), the District of Arizona (alternative choice of plaintiffs in the District of Arizona Casey action), the Central District of California (alternative choice of plaintiffs in the Central District of California Bodily action), the District of Massachusetts (the alternative choice of plaintiffs in two cases). Plaintiff in the Central District of California Burkhart action does not oppose centralization but requests that her action be excluded from any MDL due to its advanced procedural posture. After considering the argument of counsel,’ we find that the actions in this litigation involve common questions of fact, and that centralization in the Eastern District of Arkansas will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. All

' An action pending in the District of Arizona (Mulvania) and on the motion to centralize was dismissed during the pendency of the motion. 2 These actions, and any other related actions, are potential tag-along actions. See Panel Rules 1.1(h), 7.1 and 7.2. > Wright Medical Technology, Inc., Wright Medical Group, Inc., and Wright Medical Group, N.V. “In light of the concerns about the spread of COVID-19 virus (coronavirus), the Panel heard oral argument by videoconference at its hearing session of July 30, 2020. See Suppl. Notice of Hearing Session, MDL No. 2949 (J.P.M.L. July 14, 2020), ECF No. 104. A TRUE COPY I CERTIFY JAMES W. McCORMACK, CLERK case assigned to District Judge Pakec— □□

WwAOwe 2.4 UV VVUL □□ INVIVIT INGEN PYVLULITIOCTIt 2 PHM Vora payt cvilyv

-2- actions involve common factual questions about the design, marketing and performance of the Profemur line of modular hip implants, including both titanium femoral necks and those made of cobalt chromium (CoCr). Plaintiffs contend that the modular devices are prone to micromovements that lead to fluid ingress into the bore, which leads to fretting and corrosion in the stem-neck junction, which in turn leads to metallosis and increased blood metal levels and, at times, fracture of the devices. Centralization willavoid duplicative discovery, including costly expert discovery, on such complex issues as the design, testing, manufacturing, and marketing of the Profemur modular hip implant system and related motion practice. Further, we note that centralization is consistent with our past decisions in other similar hip implant dockets that we have centralized in the recent past. See, e.g., MDL No. 2391 — Jn re: Biomet M2a Magnum Hip Implant Prods. Liab. Litig.; MDL No. 2768 — In re: Stryker LFIT V40 Femoral Head Products Liability Litigation. Wright and Microport oppose centralization for several reasons. They argue that there are insufficient common fact questions among the actions, that informal cooperation is workable, and that centralization will prove inefficient given the varying procedural postures of the actions. We are not persuaded by these arguments. The actions share numerous questions of fact, which is not surprising in. light of the similarities of the titanium and CoCr devices. As plaintiffs note, the taper of the neck, the bore of the stem, and the tolerances between the neck and stem at their junction are identical across the entire Profemur family, regardless of the alloy used for the neck component. Moreover, as plaintiffs assert, the 2009 addition of the CoCr modular neck to the Profemur line was a product extension, and defendants’ marketing of the Profemur line was the same, regardless of the alloy of the modular neck. The surgical techniques that are published by defendants for promotion to surgeons reportedly do not account for any difference between the alloys. Further, plaintiffs assert that all Profemur devices are distributed with the same labeling and Information For Use in product packaging, and the Profemur component parts were manufactured at Wright’s facility in Arlington, Tennessee, which was later purchased by Microport. The number of actions and involved districts, and the substantial similarity of the claims asserted by the various plaintiffs, suggest to us that centralization will result in significant efficiency and convenience benefits for the parties and the courts. There already are several dozen pending cases: 41 cases and 21 potential tag-along actions, with a significant number of plaintiffs’ and defense counsel involved. Including the potential tag-along actions, 49 pending Profemur cases were filed since 2019. Placing the actions before a single judge (as opposed to several dozen) will result in a significant savings of judicial and party resources. The sheer number of counsel, cases and judges involved in this litigation. make informal coordination impractical. As an added benefit, centralization will allow for uniform resolution of discovery issues and facilitate coordination with the three Tennessee dockets (titanium neck claims, CoCr neck claims against Wright, and CoCr claims against Microport) that are being coordinated in Shelby County, Tennessee. Incorporating the more advanced actions may prove challenging, but doing so appears preferable at this stage to excluding all longer-pending actions. We are aware that prior rulings concerning motions

WwOAOD 2.420 VV VVOLVWINVIVET INGEN bMVVULTIOCEit LY VOrsgiacy Payee vviv

-3- to dismiss° and discovery also have the potential to complicate pretrial proceedings in a Profemur MDL. The advanced procedural status of some cases may weigh in favor of expedited remand for trial once the transferee judge has had the time to address any common discovery, summary judgment and Daubert issues. But we need not decide the exact course of pretrial proceedings in the handful of advanced Profemur actions, as that is a matter dedicated to the discretion of the transferee judge.° Without a doubt, there will be some individualized factual issues in each action, but these issues do not negate the efficiencies to be gained by centralization. We have previously stated that “[a]lmost all personal injury litigation involves questions of causation that are plaintiff-specific. Those differences are not an impediment to centralization where common questions of fact predominate.” Jn re: Xarelto (Rivaroxaban) Prods. Liab.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Aberdeen Claims Administration, Inc. v. Satyam Computer Services Ltd.
712 F. Supp. 2d 1381 (Judicial Panel on Multidistrict Litigation, 2010)
In re Xarelto (Rivaroxaban) Products Liability Litigation
65 F. Supp. 3d 1402 (Judicial Panel on Multidistrict Litigation, 2014)
In re Mirena IUD Products Liability Litigation
938 F. Supp. 2d 1355 (Judicial Panel on Multidistrict Litigation, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
Baker v. Wright Medical Technology, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/baker-v-wright-medical-technology-inc-caed-2020.